-+ 0.00%
-+ 0.00%
-+ 0.00%

Royalty Pharma Publishes UBS Global Biopharma Conference Transcript

PUBT·11/19/2026 17:43:03
Royalty Pharma Publishes UBS Global Biopharma Conference Transcript
  • Royalty Pharma expects annual capital deployment to rise beyond its stated $2 billion-$2.5 billion target as pharmaceutical R&D co-funding expands.
  • Christopher Hite, Greg Butz and UBS analyst Ashwani Verma attended the UBS Global Biopharma Conference on November 17, 2026.
  • Hite cited US accounting rules allowing pharmaceutical partners to expand pipeline spending through external funding without reducing earnings per share.
  • Management views Chinese royalty acquisitions as additional to existing deployment goals, targeting streams from drugs licensed to Western pharmaceutical companies.
  • Third-quarter earnings beat expectations, prompting a guidance increase; Tremfya, Voranigo and Evrysdi contributed to growth.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief on November 19, 2026, and is solely responsible for the information contained therein.